Neurodegeneration Markers in the Cerebrospinal Fluid of 100 Patients with Schizophrenia Spectrum Disorder.
NFM
SSD
amyloid
neurofilament
psychosis
tau
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
15 03 2023
15 03 2023
Historique:
pubmed:
7
10
2022
medline:
21
3
2023
entrez:
6
10
2022
Statut:
ppublish
Résumé
Schizophrenia spectrum disorders (SSD) can be associated with neurodegenerative processes causing disruption of neuronal, synaptic, or axonal integrity. Some previous studies have reported alterations of neurodegenerative markers (such as amyloid beta [Aβ], tau, or neurofilaments) in patients with SSD. However, the current state of research remains inconclusive. Therefore, the rationale of this study was to investigate established neurodegenerative markers in the cerebrospinal fluid (CSF) of a large group of patients with SSD. Measurements of Aβ1-40, Aß1-42, phospho- and total-tau in addition to neurofilament light (NFL), medium (NFM), and heavy (NFH) chains were performed in the CSF of 100 patients with SSD (60 F, 40 M; age 33.7 ± 12.0) and 39 controls with idiopathic intracranial hypertension (33 F, 6 M; age 34.6 ± 12.0) using enzyme-linked immunoassays. The NFM levels were significantly increased in SSD patients (P = .009), whereas phospho-tau levels were lower in comparison to the control group (P = .018). No other significant differences in total-tau, beta-amyloid-quotient (Aβ1-42/Aβ1-40), NFL, and NFH were identified. The findings argue against a general tauopathy or amyloid pathology in patients with SSD. However, high levels of NFM, which has been linked to regulatory functions in dopaminergic neurotransmission, were associated with SSD. Therefore, NFM could be a promising candidate for further research on SSD.
Sections du résumé
BACKGROUND
Schizophrenia spectrum disorders (SSD) can be associated with neurodegenerative processes causing disruption of neuronal, synaptic, or axonal integrity. Some previous studies have reported alterations of neurodegenerative markers (such as amyloid beta [Aβ], tau, or neurofilaments) in patients with SSD. However, the current state of research remains inconclusive. Therefore, the rationale of this study was to investigate established neurodegenerative markers in the cerebrospinal fluid (CSF) of a large group of patients with SSD.
STUDY DESIGN
Measurements of Aβ1-40, Aß1-42, phospho- and total-tau in addition to neurofilament light (NFL), medium (NFM), and heavy (NFH) chains were performed in the CSF of 100 patients with SSD (60 F, 40 M; age 33.7 ± 12.0) and 39 controls with idiopathic intracranial hypertension (33 F, 6 M; age 34.6 ± 12.0) using enzyme-linked immunoassays.
STUDY RESULTS
The NFM levels were significantly increased in SSD patients (P = .009), whereas phospho-tau levels were lower in comparison to the control group (P = .018). No other significant differences in total-tau, beta-amyloid-quotient (Aβ1-42/Aβ1-40), NFL, and NFH were identified.
CONCLUSIONS
The findings argue against a general tauopathy or amyloid pathology in patients with SSD. However, high levels of NFM, which has been linked to regulatory functions in dopaminergic neurotransmission, were associated with SSD. Therefore, NFM could be a promising candidate for further research on SSD.
Identifiants
pubmed: 36200879
pii: 6749565
doi: 10.1093/schbul/sbac135
pmc: PMC10016411
doi:
Substances chimiques
Amyloid beta-Peptides
0
APP protein, human
0
Biomarkers
0
MAPT protein, human
0
neurofilament protein H
108688-71-7
neurofilament protein L
0
neurofilament protein M
111365-29-8
Neurofilament Proteins
0
Peptide Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
464-473Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
JAMA Psychiatry. 2020 Feb 1;77(2):201-210
pubmed: 31664453
Schizophr Res. 2021 May;231:205-213
pubmed: 33887648
Biol Psychiatry. 2022 Aug 15;92(4):261-274
pubmed: 35606187
Psychiatr Q. 2017 Dec;88(4):921-928
pubmed: 28342141
J Neurol. 2020 Jan;267(1):162-167
pubmed: 31595378
Am J Geriatr Psychiatry. 2016 Oct;24(10):923-39
pubmed: 27526990
Eur Arch Psychiatry Clin Neurosci. 2003 Apr;253(2):100-2
pubmed: 12799749
Mol Psychiatry. 2002;7(4):405-11
pubmed: 11986984
Int J Neuropsychopharmacol. 2007 Jun;10(3):321-33
pubmed: 16734940
Fluids Barriers CNS. 2022 Jul 29;19(1):61
pubmed: 35906648
Eur J Neurol. 2020 Jul;27(7):1164-1169
pubmed: 32243670
Transl Neurodegener. 2020 Jun 23;9(1):27
pubmed: 32576262
Am J Hum Genet. 2003 Jul;73(1):34-48
pubmed: 12802786
Brain Sci. 2020 Jun 08;10(6):
pubmed: 32521749
Brain Res Bull. 2016 Sep;126(Pt 3):334-346
pubmed: 27609296
Arch Neurol. 1999 Jun;56(6):673-80
pubmed: 10369305
Hypertension. 2017 Aug;70(2):357-364
pubmed: 28584012
J Neuropathol Exp Neurol. 1988 Nov;47(6):642-53
pubmed: 2459315
FEBS Lett. 2001 Oct 19;507(1):81-7
pubmed: 11682063
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):
pubmed: 25539505
Nat Commun. 2020 Feb 10;11(1):812
pubmed: 32041951
Compr Psychiatry. 2020 Oct;102:152196
pubmed: 32927367
Clin Chem Lab Med. 2015 Sep 1;53(10):1575-84
pubmed: 25720124
Alzheimers Dement. 2017 Aug;13(8):885-892
pubmed: 28222302
Int J Geriatr Psychiatry. 2011 Jun;26(6):640-8
pubmed: 20872913
Proteomics Clin Appl. 2007 Oct;1(10):1291-305
pubmed: 21136626
Front Neurol. 2015 Nov 27;6:247
pubmed: 26640457
J Neurol. 2007 Jan;254(1):20-5
pubmed: 17508137
J Psychiatr Res. 1982-1983;17(4):319-34
pubmed: 7187776
Transl Psychiatry. 2021 May 21;11(1):308
pubmed: 34021122
Ann Clin Transl Neurol. 2014 Aug;1(8):544-53
pubmed: 25356426
JAMA Neurol. 2019 Sep 01;76(9):1035-1048
pubmed: 31206160
J Psychiatr Res. 2010 Oct;44(14):989-91
pubmed: 20381070
Clin Chem. 2006 Feb;52(2):332-4
pubmed: 16449222
J Stroke Cerebrovasc Dis. 2020 Jun;29(6):104813
pubmed: 32305278
Neural Plast. 2017;2017:4153076
pubmed: 28634551
J Alzheimers Dis. 2016 May 31;53(3):1121-32
pubmed: 27258423
Mol Psychiatry. 2015 Aug;20(8):986-94
pubmed: 25869803
Aust N Z J Psychiatry. 2022 Oct;56(10):1295-1305
pubmed: 35179048
J Psychiatr Res. 2021 Aug;140:141-148
pubmed: 34116440
J Neuroimmunol. 2014 Apr 15;269(1-2):68-75
pubmed: 24636402
Electrophoresis. 2012 Dec;33(24):3738-44
pubmed: 23161113
J Psychiatr Res. 2021 Dec;144:255-261
pubmed: 34700214
Cephalalgia. 2020 Oct;40(12):1346-1354
pubmed: 32727204
Schizophr Bull. 2014 Jul;40(4):721-8
pubmed: 24870447
J Neuropathol Exp Neurol. 1988 Jan;47(1):9-18
pubmed: 3334727
Sci Rep. 2020 Aug 31;10(1):14271
pubmed: 32868793
J Psychiatr Res. 2019 Jun;113:137-140
pubmed: 30953863
Transl Psychiatry. 2018 Aug 24;8(1):167
pubmed: 30143609
Biol Sex Differ. 2020 Jun 19;11(1):33
pubmed: 32560743
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
J Neurosci. 2012 May 2;32(18):6209-19
pubmed: 22553027
Neurology. 2022 Apr 5;98(14):e1489-e1498
pubmed: 35145006
Eur J Neurol. 2010 Apr;17(4):562-6
pubmed: 19968709
J Psychiatr Res. 2010 Dec;44(16):1176-89
pubmed: 20471030
Ann Clin Lab Sci. 2006 Spring;36(2):151-6
pubmed: 16682510
J Neurosci. 1998 Jan 15;18(2):720-30
pubmed: 9425014
Alzheimers Dement. 2014 Oct;10(5 Suppl):S390-S394.e2
pubmed: 24269268
J Neurol Neurosurg Psychiatry. 2020 May;91(5):503-511
pubmed: 32132225
Schizophr Bull. 2021 Jan 23;47(1):197-206
pubmed: 32681179
Transl Psychiatry. 2020 Aug 12;10(1):279
pubmed: 32782247
Indian J Psychiatry. 2010 Jan;52(1):21-7
pubmed: 20174514
J Neurosci. 2002 Jul 15;22(14):5920-30
pubmed: 12122054